Article

Allergan introduces new preservative-free drop

Allergan Inc. has introduced an over-the-counter artificial tear (Optive Sensitive Preservative-Free Lubricant Eye Drops) for patients who have dry eye or dryness following LASIK.

Irvine, CA-Allergan Inc. has introduced an over-the-counter artificial tear (Optive Sensitive Preservative-Free Lubricant Eye Drops) for patients who have dry eye or dryness following LASIK.

The drop is part of a line of artificial tears with a dual-action formula designed to provide a lubricating, hydrating, protective shield on the surface of the eye and also penetrate below the surface to provide corneal epithelial cells osmoprotection from excessive salt levels.

In a 30-day, randomized, controlled trial of 316 patients with dry eye, 157 patients who received the new artificial tear saw a statistically significant improvement in six common signs and symptoms of dry eye when compared with another drop (Refresh Plus, Allergan), according to the company. In a separate 90-day, randomized, controlled trial of 228 patients who had undergone LASIK, those who used the new drop experienced less ocular surface staining at 2 weeks after surgery when compared with patients who had used the other aforementioned artificial tear, according to the company. This trial also demonstrated a statistically significant improvement from baseline in patients’ evaluation of dry eye symptoms, Allergan officials reported.
 
“[The new drop] has undergone testing and has been shown to perform excellently in both dry eye and post-LASIK patient populations,” said Joseph Vehige, OD, the company’s senior director of consumer eye-care research and development. “We are pleased to be able to offer . . . a new option in managing their signs and symptoms of dry eye.”

The new formulation is available in unit-dose vials.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.